InvestorsHub Logo
Followers 12
Posts 472
Boards Moderated 0
Alias Born 06/20/2020

Re: None

Thursday, 07/22/2021 10:51:52 AM

Thursday, July 22, 2021 10:51:52 AM

Post# of 403174
In vitro data presented at ASV 2021 for Alphavirus and Bunyavirus used brilacidin at a concentration of 20µm and included pretreatment of the virus with brilacidin. The concentration of 20µm converts to a dose >1.5 mg/kg (almost 2X the highest single dose used in the ABSSSI P2 trial) while the pretreatment improves the potency of brilacidin. Both this dose and pretreatment of brilacidin are not possible when using brilacidin as a therapeutic in the real world. This is PoC stuff, and I know that investors were not the intended audience, but I was hoping for something to come out of it that would apply to the real world and move the share price.

2 slides seem to be missing from the deck. The slides are numbered 1-21 but there are 19 slides in the PDF. Slide 6 or 7 and 13 are not included.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News